<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="61566">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02304432</url>
  </required_header>
  <id_info>
    <org_study_id>1R21MH105732</org_study_id>
    <nct_id>NCT02304432</nct_id>
  </id_info>
  <brief_title>Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine</brief_title>
  <acronym>DCS</acronym>
  <official_title>Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mclean Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mclean Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of d-cycloserine (DCS) as an
      augmentation strategy in two psychotic patients with a triplication (4 copies) of the
      glycine decarboxylase (GLDC) gene. Subjects will first undergo an eight-week open-label arm
      of treatment with DCS (50 mg/d) followed by six 6-week double-blind placebo-controlled
      exposures to DCS or placebo. The length of each double-blind arm is limited to six weeks to
      minimize the length of symptom exacerbation experienced by the subjects when they are
      receiving placebo. The randomization scheme will allow two consecutive exposures to DCS, but
      will not allow two consecutive exposures to placebo, again to minimize the length of any
      symptom exacerbation. At the end of the open-label DCS trial, the following procedures will
      be carried out: structural MRI (3T), proton 1H MRS (4T), fMRI (3T), steady-state auditory
      evoked potentials, and electroretinogram recordings. In addition, 1H MRS (4T) for 2 hours
      after a single oral dose of a DCS will be assessed. Baseline data on all of these measures
      were previously obtained as part of a different study registered in clinical trials.gov -
      NCT01720316). Positive, negative, and affective symptoms and neurocognitive function as well
      as plasma levels of large neutral and large and small neutral and excitatory amino acids and
      psychotropic drug levels will be assessed periodically. Pharmaceutical grade DCS) or placebo
      will be compounded and dispensed by the McLean Hospital Pharmacy.

      The investigators hypothesize that mutation carriers will have reduced endogenous brain
      glycine and GABA levels and increased brain glutamate and glutamine levels. DCS
      administration will increase brain glycine in the two carriers compared to baseline and
      treatment with glycine (0.8g/kg).

      The investigators hypothesize reduced activation of magnocellular pathways and abnormal ERPs
      modulated by NMDA in mutation carriers compared with non-carrier family members and
      controls.

      . The investigators hypothesize that DCS, but not placebo, will improve positive, negative
      and affective symptoms as well as neurocognitive function.

      The investigators also hypothesize that DCS will improve clinical and cognitive functioning,
      will partially normalize decreased baseline glycine and GABA and increased glutamate and
      glutamine, and will partially normalize magnocellular pathway activation and abnormal evoked
      potentials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple rare structural variants of relatively recent evolutionary origin are recognized as
      important risk factors for schizophrenia (SZ) and other neurodevelopmental disorders (e.g.,
      autism spectrum disorders, mental retardation, epilepsy) with odds ratios as high as 7-30.
      We have found a de novo structural rearrangement on chromosome 9p24.1 in two psychotic
      patients. One of the genes in this region is the gene encoding glycine decarboxylase (GLDC),
      which affects brain glycine metabolism. GLDC encodes the glycine decarboxylase or glycine
      cleavage system P-protein, which is involved in degradation of glycine in glia cells.
      Carriers of the GLDC triplication would be expected to have low levels of brain Gly,
      resulting in NMDA receptor-mediated hypofunction, which has been strongly implicated in the
      pathophysiology of schizophrenia.

      There is an extensive literature on the effects of NMDA enhancing agents on positive,
      negative, and depressive symptoms and on neurocognitive function. Although many studies have
      reported positive results in at least one symptom domain, the results of other studies have
      been negative or ambiguous. Factors likely to contribute to this variability include:
      mechanism of action of the agent, compliance, concurrent treatment with first- vs second
      generation antipsychotic drugs, baseline glycine blood levels, presence/absence of
      kynurenine pathway metabolic abnormalities and individual differences in brain glycine
      uptake and metabolism . Genetic variants that impact the synthesis and breakdown of glycine,
      glutamate, or other modulators of NMDA receptor function are also likely to have significant
      effects. Although DCS augmentation has shown variable efficacy in patients unselected for
      having a mutation that would be expected to lower brain glycine levels, the GLDC
      triplication in the two carriers in this study would be expected to result in unusually low
      brain glycine levels, supporting its therapeutic potential as an augmentation strategy.

      Thus, it is important to evaluate the therapeutic efficacy of DCS augmentation in
      individuals in whom there is a high prior probability of therapeutic benefit and to
      characterize the neurobiology of this mutation in terms of brain metabolites, brain
      function, and the pharmacokinetics of glycine metabolism using well-established methods.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical and neurocognitive response to DCS augmentation; change in amino acid levels with DCS augmentation</measure>
    <time_frame>44 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain and plasma glycine levels will be measured with proton magnetic resonance spectroscopy at 4T and analytically, respectively</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in glycine levels after oral DCS administration</measure>
    <time_frame>2 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Open label DCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>D-cycloserine (seromycin), 50 mg/d capsule x 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DCS or placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized to DCS or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D-cycloserine</intervention_name>
    <arm_group_label>Open label DCS</arm_group_label>
    <arm_group_label>DCS or placebo</arm_group_label>
    <other_name>Seromycin (d-cycloserine)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>DCS or placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Carriers of a triplication in the glycine decarboxylase gene

        Exclusion Criteria:

          -  Not carriers of a triplication in the glycine decarboxylase gene
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>33 Years</minimum_age>
    <maximum_age>62 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah L. Levy, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mclean Hospital</affiliation>
  </overall_official>
  <results_reference>
    <citation>Sebat J, Levy DL, McCarthy SE. Rare structural variants in schizophrenia: one disorder, multiple mutations; one mutation, multiple disorders. Trends Genet. 2009 Dec;25(12):528-35. doi: 10.1016/j.tig.2009.10.004. Epub 2009 Oct 31. Review.</citation>
    <PMID>19883952</PMID>
  </results_reference>
  <results_reference>
    <citation>Malhotra D, McCarthy S, Michaelson JJ, Vacic V, Burdick KE, Yoon S, Cichon S, Corvin A, Gary S, Gershon ES, Gill M, Karayiorgou M, Kelsoe JR, Krastoshevsky O, Krause V, Leibenluft E, Levy DL, Makarov V, Bhandari A, Malhotra AK, McMahon FJ, Nöthen MM, Potash JB, Rietschel M, Schulze TG, Sebat J. High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron. 2011 Dec 22;72(6):951-63. doi: 10.1016/j.neuron.2011.11.007.</citation>
    <PMID>22196331</PMID>
  </results_reference>
  <results_reference>
    <citation>Heinzen EL, Radtke RA, Urban TJ, Cavalleri GL, Depondt C, Need AC, Walley NM, Nicoletti P, Ge D, Catarino CB, Duncan JS, Kasperaviciūte D, Tate SK, Caboclo LO, Sander JW, Clayton L, Linney KN, Shianna KV, Gumbs CE, Smith J, Cronin KD, Maia JM, Doherty CP, Pandolfo M, Leppert D, Middleton LT, Gibson RA, Johnson MR, Matthews PM, Hosford D, Kälviäinen R, Eriksson K, Kantanen AM, Dorn T, Hansen J, Krämer G, Steinhoff BJ, Wieser HG, Zumsteg D, Ortega M, Wood NW, Huxley-Jones J, Mikati M, Gallentine WB, Husain AM, Buckley PG, Stallings RL, Podgoreanu MV, Delanty N, Sisodiya SM, Goldstein DB. Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet. 2010 May 14;86(5):707-18. doi: 10.1016/j.ajhg.2010.03.018. Epub 2010 Apr 15.</citation>
    <PMID>20398883</PMID>
  </results_reference>
  <results_reference>
    <citation>Weiss LA, Shen Y, Korn JM, Arking DE, Miller DT, Fossdal R, Saemundsen E, Stefansson H, Ferreira MA, Green T, Platt OS, Ruderfer DM, Walsh CA, Altshuler D, Chakravarti A, Tanzi RE, Stefansson K, Santangelo SL, Gusella JF, Sklar P, Wu BL, Daly MJ; Autism Consortium.. Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med. 2008 Feb 14;358(7):667-75. doi: 10.1056/NEJMoa075974. Epub 2008 Jan 9.</citation>
    <PMID>18184952</PMID>
  </results_reference>
  <results_reference>
    <citation>McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, Perkins DO, Dickel DE, Kusenda M, Krastoshevsky O, Krause V, Kumar RA, Grozeva D, Malhotra D, Walsh T, Zackai EH, Kaplan P, Ganesh J, Krantz ID, Spinner NB, Roccanova P, Bhandari A, Pavon K, Lakshmi B, Leotta A, Kendall J, Lee YH, Vacic V, Gary S, Iakoucheva LM, Crow TJ, Christian SL, Lieberman JA, Stroup TS, Lehtimäki T, Puura K, Haldeman-Englert C, Pearl J, Goodell M, Willour VL, Derosse P, Steele J, Kassem L, Wolff J, Chitkara N, McMahon FJ, Malhotra AK, Potash JB, Schulze TG, Nöthen MM, Cichon S, Rietschel M, Leibenluft E, Kustanovich V, Lajonchere CM, Sutcliffe JS, Skuse D, Gill M, Gallagher L, Mendell NR; Wellcome Trust Case Control Consortium., Craddock N, Owen MJ, O'Donovan MC, Shaikh TH, Susser E, Delisi LE, Sullivan PF, Deutsch CK, Rapoport J, Levy DL, King MC, Sebat J. Microduplications of 16p11.2 are associated with schizophrenia. Nat Genet. 2009 Nov;41(11):1223-7. doi: 10.1038/ng.474. Epub 2009 Oct 25.</citation>
    <PMID>19855392</PMID>
  </results_reference>
  <results_reference>
    <citation>Olney JW, Farber NB. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry. 1995 Dec;52(12):998-1007.</citation>
    <PMID>7492260</PMID>
  </results_reference>
  <results_reference>
    <citation>Coyle JT. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):365-84. Epub 2006 Jun 14. Review.</citation>
    <PMID>16773445</PMID>
  </results_reference>
  <results_reference>
    <citation>Javitt DC. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. Int Rev Neurobiol. 2007;78:69-108. Review.</citation>
    <PMID>17349858</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsai GE, Lin PY. Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Curr Pharm Des. 2010;16(5):522-37. Review.</citation>
    <PMID>19909229</PMID>
  </results_reference>
  <results_reference>
    <citation>Lin CH, Lane HY, Tsai GE. Glutamate signaling in the pathophysiology and therapy of schizophrenia. Pharmacol Biochem Behav. 2012 Feb;100(4):665-77. doi: 10.1016/j.pbb.2011.03.023. Epub 2011 Apr 1. Review.</citation>
    <PMID>21463651</PMID>
  </results_reference>
  <results_reference>
    <citation>Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Horowitz A, Kelly D. Double-blind, placebo-controlled, crossover trial of glycine adjuvant therapy for treatment-resistant schizophrenia. Br J Psychiatry. 1996 Nov;169(5):610-7.</citation>
    <PMID>8932891</PMID>
  </results_reference>
  <results_reference>
    <citation>Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M. Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen Psychiatry. 1999 Jan;56(1):29-36.</citation>
    <PMID>9892253</PMID>
  </results_reference>
  <results_reference>
    <citation>Heresco-Levy U, Javitt DC. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res. 2004 Feb 1;66(2-3):89-96.</citation>
    <PMID>15061240</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsai G, Yang P, Chung LC, Lange N, Coyle JT. D-serine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 1998 Dec 1;44(11):1081-9.</citation>
    <PMID>9836012</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsai GE, Yang P, Chung LC, Tsai IC, Tsai CW, Coyle JT. D-serine added to clozapine for the treatment of schizophrenia. Am J Psychiatry. 1999 Nov;156(11):1822-5.</citation>
    <PMID>10553752</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004 Mar 1;55(5):452-6.</citation>
    <PMID>15023571</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsai GE, Yang P, Chang YC, Chong MY. D-alanine added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2006 Feb 1;59(3):230-4. Epub 2005 Sep 9.</citation>
    <PMID>16154544</PMID>
  </results_reference>
  <results_reference>
    <citation>Javitt DC, Silipo G, Cienfuegos A, Shelley AM, Bark N, Park M, Lindenmayer JP, Suckow R, Zukin SR. Adjunctive high-dose glycine in the treatment of schizophrenia. Int J Neuropsychopharmacol. 2001 Dec;4(4):385-91.</citation>
    <PMID>11806864</PMID>
  </results_reference>
  <results_reference>
    <citation>Goff DC, Tsai G, Manoach DS, Flood J, Darby DG, Coyle JT. D-cycloserine added to clozapine for patients with schizophrenia. Am J Psychiatry. 1996 Dec;153(12):1628-30.</citation>
    <PMID>8942463</PMID>
  </results_reference>
  <results_reference>
    <citation>Lane HY, Liu YC, Huang CL, Chang YC, Liau CH, Perng CH, Tsai GE. Sarcosine (N-methylglycine) treatment for acute schizophrenia: a randomized, double-blind study. Biol Psychiatry. 2008 Jan 1;63(1):9-12. Epub 2007 Jul 20.</citation>
    <PMID>17659263</PMID>
  </results_reference>
  <results_reference>
    <citation>Goff DC, Henderson DC, Evins AE, Amico E. A placebo-controlled crossover trial of D-cycloserine added to clozapine in patients with schizophrenia. Biol Psychiatry. 1999 Feb 15;45(4):512-4.</citation>
    <PMID>10071726</PMID>
  </results_reference>
  <results_reference>
    <citation>Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia. Am J Psychiatry. 2000 May;157(5):826-8.</citation>
    <PMID>10784481</PMID>
  </results_reference>
  <results_reference>
    <citation>Duncan EJ, Szilagyi S, Schwartz MP, Bugarski-Kirola D, Kunzova A, Negi S, Stephanides M, Efferen TR, Angrist B, Peselow E, Corwin J, Gonzenbach S, Rotrosen JP. Effects of D-cycloserine on negative symptoms in schizophrenia. Schizophr Res. 2004 Dec 1;71(2-3):239-48. Review.</citation>
    <PMID>15474895</PMID>
  </results_reference>
  <results_reference>
    <citation>van Berckel BN, Evenblij CN, van Loon BJ, Maas MF, van der Geld MA, Wynne HJ, van Ree JM, Kahn RS. D-cycloserine increases positive symptoms in chronic schizophrenic patients when administered in addition to antipsychotics: a double-blind, parallel, placebo-controlled study. Neuropsychopharmacology. 1999 Aug;21(2):203-10.</citation>
    <PMID>10432468</PMID>
  </results_reference>
  <results_reference>
    <citation>Wonodi I, Schwarcz R. Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull. 2010 Mar;36(2):211-8. doi: 10.1093/schbul/sbq002. Epub 2010 Feb 10. Review.</citation>
    <PMID>20147364</PMID>
  </results_reference>
  <results_reference>
    <citation>Erhardt S, Schwieler L, Nilsson L, Linderholm K, Engberg G. The kynurenic acid hypothesis of schizophrenia. Physiol Behav. 2007 Sep 10;92(1-2):203-9. Epub 2007 May 21.</citation>
    <PMID>17573079</PMID>
  </results_reference>
  <results_reference>
    <citation>Kaufman MJ, Prescot AP, Ongur D, Evins AE, Barros TL, Medeiros CL, Covell J, Wang L, Fava M, Renshaw PF. Oral glycine administration increases brain glycine/creatine ratios in men: a proton magnetic resonance spectroscopy study. Psychiatry Res. 2009 Aug 30;173(2):143-9. doi: 10.1016/j.pscychresns.2009.03.004. Epub 2009 Jun 24.</citation>
    <PMID>19556112</PMID>
  </results_reference>
  <results_reference>
    <citation>Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry. 2007 Oct;164(10):1593-602.</citation>
    <PMID>17898352</PMID>
  </results_reference>
  <results_reference>
    <citation>Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia. Arch Gen Psychiatry. 1999 Jan;56(1):21-7.</citation>
    <PMID>9892252</PMID>
  </results_reference>
  <results_reference>
    <citation>Goff DC, Herz L, Posever T, Shih V, Tsai G, Henderson DC, Freudenreich O, Evins AE, Yovel I, Zhang H, Schoenfeld D. A six-month, placebo-controlled trial of D-cycloserine co-administered with conventional antipsychotics in schizophrenia patients. Psychopharmacology (Berl). 2005 Apr;179(1):144-50. Epub 2004 Oct 21.</citation>
    <PMID>15502972</PMID>
  </results_reference>
  <results_reference>
    <citation>Goff DC, Cather C, Gottlieb JD, Evins AE, Walsh J, Raeke L, Otto MW, Schoenfeld D, Green MF. Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study. Schizophr Res. 2008 Dec;106(2-3):320-7. doi: 10.1016/j.schres.2008.08.012. Epub 2008 Sep 16.</citation>
    <PMID>18799288</PMID>
  </results_reference>
  <results_reference>
    <citation>Heresco-Levy U, Javitt DC, Ermilov M, Silipo G, Shimoni J. Double-blind, placebo-controlled, crossover trial of D-cycloserine adjuvant therapy for treatment-resistant schizophrenia. Int J Neuropsychopharmacol. 1998 Dec;1(2):131-135.</citation>
    <PMID>11281957</PMID>
  </results_reference>
  <results_reference>
    <citation>Heresco-Levy U, Ermilov M, Shimoni J, Shapira B, Silipo G, Javitt DC. Placebo-controlled trial of D-cycloserine added to conventional neuroleptics, olanzapine, or risperidone in schizophrenia. Am J Psychiatry. 2002 Mar;159(3):480-2.</citation>
    <PMID>11870017</PMID>
  </results_reference>
  <results_reference>
    <citation>Prescot AP, de B Frederick B, Wang L, Brown J, Jensen JE, Kaufman MJ, Renshaw PF. In vivo detection of brain glycine with echo-time-averaged (1)H magnetic resonance spectroscopy at 4.0 T. Magn Reson Med. 2006 Mar;55(3):681-6.</citation>
    <PMID>16453318</PMID>
  </results_reference>
  <results_reference>
    <citation>Martínez A, Hillyard SA, Dias EC, Hagler DJ Jr, Butler PD, Guilfoyle DN, Jalbrzikowski M, Silipo G, Javitt DC. Magnocellular pathway impairment in schizophrenia: evidence from functional magnetic resonance imaging. J Neurosci. 2008 Jul 23;28(30):7492-500. doi: 10.1523/JNEUROSCI.1852-08.2008. Erratum in: J Neurosci. 2008 Sep;28(37):9319.</citation>
    <PMID>18650327</PMID>
  </results_reference>
  <results_reference>
    <citation>Butler PD, Schechter I, Zemon V, Schwartz SG, Greenstein VC, Gordon J, Schroeder CE, Javitt DC. Dysfunction of early-stage visual processing in schizophrenia. Am J Psychiatry. 2001 Jul;158(7):1126-33.</citation>
    <PMID>11431235</PMID>
  </results_reference>
  <results_reference>
    <citation>Jensen JE, Licata SC, Ongür D, Friedman SD, Prescot AP, Henry ME, Renshaw PF. Quantification of J-resolved proton spectra in two-dimensions with LCModel using GAMMA-simulated basis sets at 4 Tesla. NMR Biomed. 2009 Aug;22(7):762-9. doi: 10.1002/nbm.1390.</citation>
    <PMID>19388001</PMID>
  </results_reference>
  <results_reference>
    <citation>Ongür D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen BM, Renshaw PF. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry. 2008 Oct 15;64(8):718-26. doi: 10.1016/j.biopsych.2008.05.014. Epub 2008 Jul 7.</citation>
    <PMID>18602089</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 30, 2017</lastchanged_date>
  <firstreceived_date>November 26, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mclean Hospital</investigator_affiliation>
    <investigator_full_name>Deborah L. Levy</investigator_full_name>
    <investigator_title>Director, Psychology Research Laboratory</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cycloserine</mesh_term>
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
